EXEL vs NBIX: stock comparison and AI forecast
Exelixis, Inc. (EXEL) and Neurocrine Biosciences Inc (NBIX) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
EXEL Exelixis, Inc.
- Price
- $72.31 +62.8% · 6M
- Market Cap
- $17.64B
- P/E Ratio
- 26.0x
- Size
- large-cap
- AI Forecast
NBIX Neurocrine Biosciences Inc
- Price
- $146.38 +11.2% · 6M
- Market Cap
- $14.88B
- P/E Ratio
- 21.2x
- Size
- large-cap
- AI Forecast
- NO CURRENT FORECAST
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- EXEL is 1.2 times larger than NBIX by market capitalization ($17.64B against $14.88B).
- NBIX trades at 21.2 times trailing earnings, EXEL at 26.0 times.
- Over the last six months EXEL returned +62.8% and NBIX +11.2%.
- EXEL turns 33.7% of its revenue into net income, against 20.9% for NBIX.
- NBIX carries 0.45 times debt per unit of equity, against 0.37 times for EXEL.
- Both companies share the SEC industry classification Biological Products, (No Diagnostic Substances).
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | EXEL | NBIX |
|---|---|---|
| Market Cap | $17.64B | $14.88B |
| P/E Ratio | 26.01x | 21.18x |
| P/B Ratio | 9.62x | 4.03x |
| EPS | $2.78 | $6.91 |
| Book Value/Share | $7.52 | $36.34 |
| Revenue/Share | $9.61 | $33.19 |
| FCF/Share | $3.92 | $8.56 |
Profitability & Margins
| Metric | EXEL | NBIX |
|---|---|---|
| ROE | 42.7% | 19.1% |
| ROA | 31.1% | 13.2% |
| ROIC | 41.5% | 17.7% |
| Gross Margin | 96.4% | 98.4% |
| Operating Margin | 37.6% | 23.6% |
| Net Margin | 33.7% | 20.9% |
| EBT Margin | 37.6% | 27.9% |
| Tax Rate | 18.2% | 25.0% |
Financial Health
| Metric | EXEL | NBIX |
|---|---|---|
| Current Ratio | 3.21x | 1.87x |
| Quick Ratio | 3.14x | 1.75x |
| D/E Ratio | 0.37x | 0.45x |
| Financial Leverage | 1.37x | 1.45x |
| Interest Coverage | 6.4x | 56.1x |
| Working Capital | $910M | $763M |
Cash Flow
| Metric | EXEL | NBIX |
|---|---|---|
| Operating Cash Flow | $884M | $898M |
| Free Cash Flow | $957M | $870M |
| Capital Spending | $73M | -$28M |
| OCF Growth YoY | 26.3% | 58.3% |
| FCF Growth YoY | 42.5% | 64.6% |
| FCF/Sales | 40.8% | 25.8% |
| CapEx/Sales | 3.1% | 0.8% |
Operational Efficiency
| Metric | EXEL | NBIX |
|---|---|---|
| Asset Turnover | 0.93x | 0.63x |
| Receivables Turnover | 7.1x | 3.8x |
| Inventory Turnover | 2.8x | 0.5x |
| Fixed Assets Turnover | 26.9x | 37.3x |
| Days Sales Outstanding | 51 days | 96 days |
| Days Inventory | 130 days | 694 days |
| Payables Period | 134 days | 946 days |
| Cash Conversion Cycle | 47 days | -156 days |
Income Statement
| Metric | EXEL | NBIX |
|---|---|---|
| Total Revenue | $2.35B | $3.37B |
| Operating Income | $872M | $795M |
| Net Income | $783M | $706M |
| R&D Expense | $825M | $1.13B |
| SG&A Expense | $519M | $1.35B |
| Cost of Goods Sold | $84M | $55M |
Dividend & Shareholder Information
| Metric | EXEL | NBIX |
|---|---|---|
| Shares Outstanding | 244M | 102M |
| Net Income Growth | 50.1% | 102.6% |
| EPS Growth | 58.0% | 85.8% |
EXEL vs NBIX: stock comparison and AI forecast
Which is bigger, EXEL or NBIX?
EXEL is 1.2 times larger than NBIX by market capitalization ($17.64B against $14.88B).
Which is cheaper on earnings, EXEL or NBIX?
NBIX trades at 21.2 times trailing earnings, EXEL at 26.0 times.
Which stock performed better over the last six months, EXEL or NBIX?
Over the last six months EXEL returned +62.8% and NBIX +11.2%.
Which one does Intratio's AI model rank higher, EXEL or NBIX?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.